Usefulness of Non TNF Usage in RA Patients

Phase 2

Recruiting

• Conditions: Rheumatoid Arthritis

• Registration Number: NCT03784261
• Lead Sponsor: Shinshu University

Brief Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:

1. Sarilumab treatment for 12 months

2. Tocilizmab treatment for 12 months

3. Abatacept treatment for 12 months

Detailed Description

Not available

Study Timeline

• Study Start: 2018-12-17
• Study First Submitted: 2018-12-17
• Study First Submitted QC: 2018-12-20
• Study First Posted: 2018-12-21
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-20
• Last Update Posted: 2021-09-21
• Primary Completion: 2022-12-16
• Study Completion: 2024-12-16

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

・RA patients

Exclusion Criteria

• Not RA patients
• RA patients who are allergic to the drugs, refused to do this research, or who are pregnant

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change from Baseline Values of DAS28-CRP	Baseline and 1 year	Assessment of efficacy in rheumatoid arthritis patients for 1 year treated by salirumab (N=30), tocilizumab (N=30), or abatacept (N=30).
Assessment of adverse event in rheumatoid arthritis patients for 1 year treated by salirumab (N=30), tocilizumab (N=30), or abatacept (N=30).	at 1 year

Trial Locations

Locations (1)

Yukio Nakamura; 🇯🇵 Matsumoto, Nagano, Japan